Quality and safety requirements for sustainable phage therapy products.

Détails

Ressource 1Télécharger: 25585954_BIB_2CDEAF7F3438.pdf (186.92 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_2CDEAF7F3438
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Quality and safety requirements for sustainable phage therapy products.
Périodique
Pharmaceutical Research
Auteur(s)
Pirnay J.P., Blasdel B.G., Bretaudeau L., Buckling A., Chanishvili N., Clark J.R., Corte-Real S., Debarbieux L., Dublanchet A., De Vos D., Gabard J., Garcia M., Goderdzishvili M., Górski A., Hardcastle J., Huys I., Kutter E., Lavigne R., Merabishvili M., Olchawa E., Parikka K.J., Patey O., Pouilot F., Resch G., Rohde C., Scheres J., Skurnik M., Vaneechoutte M., Van Parys L., Verbeken G., Zizi M., Van den Eede G.
ISSN
1573-904X (Electronic)
ISSN-L
0724-8741
Statut éditorial
Publié
Date de publication
2015
Volume
32
Numéro
7
Pages
2173-2179
Langue
anglais
Résumé
The worldwide antibiotic crisis has led to a renewed interest in phage therapy. Since time immemorial phages control bacterial populations on Earth. Potent lytic phages against bacterial pathogens can be isolated from the environment or selected from a collection in a matter of days. In addition, phages have the capacity to rapidly overcome bacterial resistances, which will inevitably emerge. To maximally exploit these advantage phages have over conventional drugs such as antibiotics, it is important that sustainable phage products are not submitted to the conventional long medicinal product development and licensing pathway. There is a need for an adapted framework, including realistic production and quality and safety requirements, that allowsa timely supplying of phage therapy products for 'personalized therapy' or for public health or medical emergencies. This paper enumerates all phage therapy product related quality and safety risks known to the authors, as well as the tests that can be performed to minimize these risks, only to the extent needed to protect the patients and to allow and advance responsible phage therapy and research.
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/06/2015 13:23
Dernière modification de la notice
20/08/2019 14:11
Données d'usage